DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Update

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) was the target of a large growth in short interest in the month of February. As of February 15th, there was short interest totalling 232,300 shares, a growth of 21.1% from the January 31st total of 191,900 shares. Based on an average trading volume of 113,800 shares, the days-to-cover ratio is currently 2.0 days.

Hedge Funds Weigh In On DiaMedica Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. OMERS ADMINISTRATION Corp purchased a new position in DiaMedica Therapeutics in the 4th quarter valued at $122,000. Millennium Management LLC boosted its position in shares of DiaMedica Therapeutics by 151.8% during the 4th quarter. Millennium Management LLC now owns 84,829 shares of the company’s stock worth $461,000 after purchasing an additional 51,139 shares in the last quarter. Balyasny Asset Management L.P. purchased a new stake in shares of DiaMedica Therapeutics during the 4th quarter worth $79,000. 683 Capital Management LLC purchased a new stake in shares of DiaMedica Therapeutics during the 4th quarter worth $413,000. Finally, Jane Street Group LLC purchased a new stake in shares of DiaMedica Therapeutics during the 4th quarter worth $229,000. 10.12% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $7.00 target price on shares of DiaMedica Therapeutics in a report on Friday, November 15th.

DiaMedica Therapeutics Price Performance

Shares of DiaMedica Therapeutics stock opened at $5.77 on Friday. The firm’s fifty day simple moving average is $5.92 and its 200-day simple moving average is $4.99. The stock has a market capitalization of $246.73 million, a price-to-earnings ratio of -10.30 and a beta of 1.52. DiaMedica Therapeutics has a 12 month low of $2.14 and a 12 month high of $6.82.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.